# US 2025/0145692 A1 · Chimera molecules for sars-cov-2 and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145692 A1
- Document ID: US20250145692A1
- Status: Published application
- Kind: A1
- Application number: 18/935,511
- Filed: 2024-11-02
- Published: 2025-05-08
- Earliest claimed: 2023-11-03
- Inventors: Shaoxiao Wang; Simon Wang; Yi Wang
- Web page: https://patentgrep.com/patent/US20250145692A1

## CPC

- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 9/104: {Aminoacyltransferases (2.3.2)}
- C12Y 203/02: Aminoacyltransferases (2.3.2)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The subject matter described herein is directed to a chimera molecule such as a polypeptide or protein chimera useful for treating or preventing a viral infection or reducing the severity, incidence, or transmissibility of a viral infection, to nucleic acid molecules encoding the polypeptide or protein chimera, and to pharmaceutical compositions containing them. Also, methods of generating such antiviral polypeptide or protein chimera, of generating nucleic acid molecules encoding the antiviral polypeptide or protein chimera, and of generating pharmaceutical compositions containing the same, and methods of using the same for treatment or prevention of a SARS-CoV-2 infection, or to reduce the severity, incidence, or transmissibility of a of a SARS-CoV-2 infection, are described.

## Claims

### Claim 1

A chimera molecule having the formula:
Ab-L-P,
wherein Ab is an antibody that specifically binds to a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) Spike (S) protein antigen, the Ab is conjugated to L; L is a linker or a bond covalently or non-covalent bound to Ab and to P; and P is a ubiquitin E3 ligase.

### Claim 2 (depends on 1)

The chimera molecule of claim 1, wherein the Ab is a nanobody that specifically binds to the SARS-CoV-2 spike antigen and P is an E2 recruiting domain of the ubiquitin E3 ligase.

### Claim 3 (depends on 1)

The chimera molecule of claim 1, wherein the Spike (S) protein antigen is selected from the group consisting of Ty1 and H11-H4.

### Claim 4 (depends on 1)

The chimera molecule of claim 1, wherein Ab has an amino acid sequence selected from any one of SEQ ID NOs: 11, 22, 64, 66, 67, or 70, or an amino acid sequence having at least 85% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 11, 22, 64, 66, 67, or 70.

### Claim 5 (depends on 4)

The chimera molecule of claim 4, wherein Ab has an amino acid sequence encoded by a nucleic acid sequence selected from any one of SEQ ID NOs: 4, 17, 47, 56, 63, or 65, or an amino acid sequence encoded by a nucleic acid sequence having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 4, 17, 47, 56, 63, or 65.

### Claim 6 (depends on 1)

The chimera molecule of claim 1, wherein P has an amino acid sequence selected from any one of SEQ ID NOs: 12, 32, or 69, or an amino acid sequence having at least 85% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 12, 32, or 69.

### Claim 7 (depends on 6)

The chimera molecule of claim 6, wherein P has an amino acid sequence encoded by a nucleic acid sequence selected from any one of 5, 27, or 68, or an amino acid sequence encoded by a nucleic acid sequence having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 5, 27, or 68.

### Claim 8 (depends on 1)

The chimera molecule of claim 1, wherein Ab has an amino acid sequence selected from any one of SEQ ID NOs: 11, 22, 64, 66, 67, or 70, and P has an amino acid sequence selected from any one of SEQ ID NOs: 12, 32, or 69.

### Claim 9 (depends on 8)

The chimera molecule of claim 8, wherein Ab has an amino acid sequence encoded by a nucleic acid sequence selected from any one of SEQ ID NOs: 4, 17, 47, 56, 63, or 65, and P has an amino acid sequence encoded by a nucleic acid sequence selected from any one of 5, 27, or 68.

### Claim 10 (depends on 1)

The chimera molecule of claim 1, wherein the chimera molecule is a polypeptide or a protein chimera.

### Claim 11 (depends on 10)

The chimera molecule of claim 10, wherein the polypeptide or protein chimera has an amino acid sequence selected from any one of SEQ ID NOs: 8, 13, 20, 23, 30, 33, 39, 41, 48, 49, 57, or 58, or an amino acid sequence having at least 85% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 8, 13, 20, 23, 30, 33, 39, 41, 48, 49, 57, or 58.

### Claim 12 (depends on 11)

The chimera molecule of claim 11, wherein the polypeptide or protein chimera has an amino acid sequence encoded by a nucleic acid sequence selected from any one of SEQ ID NOs: 1, 6, 5, 18, 25, 28, 35, 37, 43, 44, 52, or 53, or an amino acid sequence encoded by a nucleic acid sequence having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs:1, 6, 5, 18, 25, 28, 35, 37, 43, 44, 52, or 53.

### Claim 13 (depends on 1)

A composition comprising the chimera molecule of claim 1, and at least one pharmaceutically acceptable excipient.

### Claim 14 (depends on 13)

A vaccine comprising the composition of claim 13.

### Claim 15 (depends on 13)

A method of treating or preventing a viral infection in a subject in need thereof, comprising administering a therapeutically effective amount of the composition of claim 13, to the subject in need thereof.

### Claim 16 (depends on 13)

A method of preventing, reducing severity, reducing incidence, or reducing transmissibility of a SARS-CoV-2 infection in a subject in need thereof, comprising administering a therapeutically effective amount of the composition of claim 13, to the subject in need thereof.

### Claim 17 (depends on 1)

A kit or article of manufacture comprising the chimera molecule of claim 1, and a package insert or label indicating that the chimera molecule can be used to treat or prevent a SARS-CoV-2 infection, to reduce severity a SARS-CoV-2 infection, to reduce incidence a SARS-CoV-2 infection, and/or to reduce transmissibility of a SARS-CoV-2 infection.
